Remarkably, the guideline incorporates the molecular classification of EC, which divides EC into four distinct categories: POLE/ultramutated (7%), tumors associated with good prognosis; microsatellite instability (MSI) hypermutated (28%), mainly endometrioid tumors associated with a mismatch repair protein deficiency (MMRd); low copy-number (LCN) (39%), or microsatellite stable (MSS) tumors without any POLE or TP53 mutations; and serous-like high copy-number (HCN) tumors (26%), which show frequent TP53 mutations and worse prognosis [9]. Here, TP53 is linked to endometrioid tumor.